{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:35:31Z","timestamp":1790292931782,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s12325-022-02421-w","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T19:18:38Z","timestamp":1674501518000},"page":"1317-1333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct03165864","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2830-5469","authenticated-orcid":false,"given":"Tomas","family":"Ganz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeta","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rivella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Dibble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"McCaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett P.","family":"Monia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrance D.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"issue":"5","key":"2421_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.130","volume":"40","author":"KE Finberg","year":"2008","unstructured":"Finberg KE, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40(5):569\u201371.","journal-title":"Nat Genet"},{"issue":"5879","key":"2421_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1126\/science.1157121","volume":"320","author":"X Du","year":"2008","unstructured":"Du X, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320(5879):1088\u201392.","journal-title":"Science"},{"issue":"1","key":"2421_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s10020-018-0011-z","volume":"24","author":"A Zivot","year":"2018","unstructured":"Zivot A, et al. Erythropoiesis: insights into pathophysiology and treatments in 2017. Mol Med (Cambridge, MA). 2018;24(1):11.","journal-title":"Mol Med (Cambridge, MA)"},{"issue":"1","key":"2421_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","volume":"11","author":"VH Haase","year":"2021","unstructured":"Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011). 2021;11(1):8\u201325.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"4","key":"2421_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RN Suragani","year":"2014","unstructured":"Suragani RN, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408\u201314.","journal-title":"Nat Med"},{"issue":"11","key":"2421_CR6","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1080\/14712598.2021.1968825","volume":"21","author":"AT Taher","year":"2021","unstructured":"Taher AT, Cappellini MD. Luspatercept for beta-thalassemia: beyond red blood cell transfusions. Expert Opin Biol Ther. 2021;21(11):1363\u201371.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"2421_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1182\/blood-2014-08-596254","volume":"125","author":"A Nai","year":"2015","unstructured":"Nai A, et al. The second transferrin receptor regulates red blood cell production in mice. Blood. 2015;125(7):1170\u20139.","journal-title":"Blood"},{"issue":"17","key":"2421_CR8","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.2018893099","volume":"134","author":"NL Parrow","year":"2019","unstructured":"Parrow NL, et al. Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis. Blood. 2019;134(17):1373\u201384.","journal-title":"Blood"},{"issue":"18","key":"2421_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood.2019002039","volume":"134","author":"J Xavier-Ferrucio","year":"2019","unstructured":"Xavier-Ferrucio J, et al. Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice. Blood. 2019;134(18):1547\u201357.","journal-title":"Blood"},{"issue":"2","key":"2421_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1084\/jem.20170396","volume":"215","author":"S Khalil","year":"2018","unstructured":"Khalil S, et al. Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med. 2018;215(2):661\u201379.","journal-title":"J Exp Med"},{"issue":"3","key":"2421_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1053\/j.seminhematol.2021.06.001","volume":"58","author":"N Maio","year":"2021","unstructured":"Maio N, et al. Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization. Semin Hematol. 2021;58(3):161\u201374.","journal-title":"Semin Hematol"},{"issue":"3","key":"2421_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/MOH.0000000000000704","volume":"29","author":"JJ Chen","year":"2022","unstructured":"Chen JJ, Zhang S. Translational control by heme-regulated elF2alpha kinase during erythropoiesis. Curr Opin Hematol. 2022;29(3):103\u201311.","journal-title":"Curr Opin Hematol"},{"issue":"31","key":"2421_CR13","doi-asserted-by":"publisher","first-page":"12727","DOI":"10.1074\/jbc.R117.781823","volume":"292","author":"R Coffey","year":"2017","unstructured":"Coffey R, Ganz T. Iron homeostasis: an anthropocentric perspective. J Biol Chem. 2017;292(31):12727\u201334.","journal-title":"J Biol Chem"},{"issue":"1","key":"2421_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/dvdy.372","volume":"251","author":"AL Fisher","year":"2022","unstructured":"Fisher AL, Babitt JL. Coordination of iron homeostasis by bone morphogenetic proteins: current understanding and unanswered questions. Dev Dyn. 2022;251(1):26\u201346.","journal-title":"Dev Dyn"},{"issue":"11","key":"2421_CR15","first-page":"3","volume":"110","author":"E Beutler","year":"2007","unstructured":"Beutler E, et al. The mask mutation identifies TMPRSS6 as an essential suppressor of hepcidin gene expression, required for normal uptake of dietary iron. ASH Ann Meeting Abstr. 2007;110(11):3.","journal-title":"ASH Ann Meeting Abstr"},{"issue":"8","key":"2421_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood.2020005222","volume":"136","author":"CA Enns","year":"2020","unstructured":"Enns CA, Jue S, Zhang AS. The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice. Blood. 2020;136(8):989\u20131001.","journal-title":"Blood"},{"issue":"6","key":"2421_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cmet.2008.09.012","volume":"8","author":"L Silvestri","year":"2008","unstructured":"Silvestri L, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008;8(6):502\u201311.","journal-title":"Cell Metab"},{"issue":"5","key":"2421_CR18","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.3390\/ijms22052650","volume":"22","author":"J Krijt","year":"2021","unstructured":"Krijt J, et al. Matriptase-2 and hemojuvelin in hepcidin regulation: in vivo immunoblot studies in mask mice. Int J Mol Sci. 2021;22(5):2650.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2421_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s42003-020-01575-z","volume":"4","author":"S Bell","year":"2021","unstructured":"Bell S, et al. A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis. Commun Biol. 2021;4(1):156.","journal-title":"Commun Biol"},{"issue":"5","key":"2421_CR20","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ajhg.2021.04.003","volume":"108","author":"Y Hu","year":"2021","unstructured":"Hu Y, et al. Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: the NHLBI TOPMed program. Am J Hum Genet. 2021;108(5):874\u201393.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"2421_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ng.456","volume":"41","author":"B Benyamin","year":"2009","unstructured":"Benyamin B, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet. 2009;41(11):1173\u20135.","journal-title":"Nat Genet"},{"issue":"11","key":"2421_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ng.462","volume":"41","author":"JC Chambers","year":"2009","unstructured":"Chambers JC, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet. 2009;41(11):1170\u20132.","journal-title":"Nat Genet"},{"issue":"5","key":"2421_CR23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood-2010-06-287292","volume":"117","author":"AS Zhang","year":"2011","unstructured":"Zhang AS, et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood. 2011;117(5):1687\u201399.","journal-title":"Blood"},{"issue":"7","key":"2421_CR24","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","volume":"140","author":"M Taylor","year":"2011","unstructured":"Taylor M, et al. Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology. 2011;140(7):2044\u201355.","journal-title":"Gastroenterology"},{"issue":"2","key":"2421_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","volume":"9","author":"YM Shah","year":"2009","unstructured":"Shah YM, et al. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab. 2009;9(2):152\u201364.","journal-title":"Cell Metab"},{"issue":"2","key":"2421_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2011-09-380337","volume":"119","author":"M Mastrogiannaki","year":"2012","unstructured":"Mastrogiannaki M, et al. Deletion of HIF-2alpha in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice. Blood. 2012;119(2):587\u201390.","journal-title":"Blood"},{"issue":"50","key":"2421_CR27","doi-asserted-by":"publisher","first-page":"E4922","DOI":"10.1073\/pnas.1314197110","volume":"110","author":"ER Anderson","year":"2013","unstructured":"Anderson ER, et al. Intestinal HIF2alpha promotes tissue-iron accumulation in disorders of iron overload with anemia. Proc Natl Acad Sci USA. 2013;110(50):E4922\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2421_CR28","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/bjh.17252","volume":"193","author":"Y Xu","year":"2021","unstructured":"Xu Y, Alfaro-Magallanes VM, Babitt JL. Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders. Br J Haematol. 2021;193(5):882\u201393.","journal-title":"Br J Haematol"},{"issue":"4","key":"2421_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.hoc.2014.04.009","volume":"28","author":"MM Heeney","year":"2014","unstructured":"Heeney MM, Finberg KE. Iron-refractory iron deficiency anemia (IRIDA). Hematol Oncol Clin North Am. 2014;28(4):637\u201352.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"2421_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3324\/haematol.2009.013136","volume":"95","author":"DR Ashby","year":"2010","unstructured":"Ashby DR, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010;95(3):505\u20138.","journal-title":"Haematologica"},{"issue":"7","key":"2421_CR31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","volume":"46","author":"L Kautz","year":"2014","unstructured":"Kautz L, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678\u201384.","journal-title":"Nat Genet"},{"issue":"12","key":"2421_CR32","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1182\/blood-2006-06-028787","volume":"108","author":"M Pak","year":"2006","unstructured":"Pak M, et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730\u20135.","journal-title":"Blood"},{"issue":"14","key":"2421_CR33","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","volume":"132","author":"J Arezes","year":"2018","unstructured":"Arezes J, et al. Erythroferrone inhibits the induction of hepcidin by BMP6. Blood. 2018;132(14):1473\u20137.","journal-title":"Blood"},{"issue":"19","key":"2421_CR34","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1182\/blood-2015-11-681494","volume":"127","author":"A Nai","year":"2016","unstructured":"Nai A, et al. Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice. Blood. 2016;127(19):2327\u201336.","journal-title":"Blood"},{"key":"2421_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2018.07.003","volume":"133","author":"T Ganz","year":"2019","unstructured":"Ganz T. Erythropoietic regulators of iron metabolism. Free Radic Biol Med. 2019;133:69\u201374.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2421_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood-2009-10-251496","volume":"116","author":"GC Bullock","year":"2010","unstructured":"Bullock GC, et al. Iron control of erythroid development by a novel aconitase-associated regulatory pathway. Blood. 2010;116(1):97\u2013108.","journal-title":"Blood"},{"issue":"2","key":"2421_CR37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jcp.1041260221","volume":"126","author":"H Kimura","year":"1986","unstructured":"Kimura H, Finch CA, Adamson JW. Hematopoiesis in the rat: Quantitation of hematopoietic progenitors and the response to iron deficiency anemia. J Cell Physiol. 1986;126(2):298\u2013306.","journal-title":"J Cell Physiol"},{"issue":"8","key":"2421_CR38","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/ajh.26189","volume":"96","author":"E Brissot","year":"2021","unstructured":"Brissot E, et al. Iron and platelets: a subtle, under-recognized relationship. Am J Hematol. 2021;96(8):1008\u201316.","journal-title":"Am J Hematol"},{"issue":"24","key":"2421_CR39","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1182\/blood-2010-04-281360","volume":"116","author":"H Forejtnikova","year":"2010","unstructured":"Forejtnikova H, et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood. 2010;116(24):5357\u201367.","journal-title":"Blood"},{"issue":"7","key":"2421_CR40","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/j.1460-2075.1991.tb07716.x","volume":"10","author":"T Dandekar","year":"1991","unstructured":"Dandekar T, et al. Identification of a novel iron-responsive element in murine and human erythroid delta-aminolevulinic acid synthase mRNA. Embo j. 1991;10(7):1903\u20139.","journal-title":"Embo j"},{"issue":"7","key":"2421_CR41","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1182\/blood-2006-08-041830","volume":"109","author":"JJ Chen","year":"2007","unstructured":"Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood. 2007;109(7):2693\u20139.","journal-title":"Blood"},{"key":"2421_CR42","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2019-129309","volume":"134","author":"R Taranath","year":"2019","unstructured":"Taranath R, et al. Regulation of iron homeostasis by PTG-300 improves disease parameters in mouse models for beta-thalassemia and hereditary hemochromatosis. Blood. 2019;134:3540.","journal-title":"Blood"},{"issue":"16_suppl","key":"2421_CR43","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1200\/JCO.2022.40.16_suppl.7003","volume":"40","author":"R Hoffman","year":"2022","unstructured":"Hoffman R, et al. Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients. J Clin Oncol. 2022;40(16_suppl):7003.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2421_CR44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/17474086.2021.1935854","volume":"14","author":"J Porter","year":"2021","unstructured":"Porter J, et al. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in beta-thalassemia: current evidence and future clinical development. Expert Rev Hematol. 2021;14(7):633\u201344.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2421_CR45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI129382","volume":"130","author":"V Manolova","year":"2019","unstructured":"Manolova V, et al. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of beta-thalassemia. J Clin Invest. 2019;130(1):491\u2013506.","journal-title":"J Clin Invest"},{"key":"2421_CR46","unstructured":"La Jolla Pharmaceutical Company: a study with LJPC-401 for the treatment of myocardial iron overload in patients with transfusion-dependent beta thalassemia; 2021. NIH National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03381833?term=LJ401-BT01&draw=2&rank=1&view=results."},{"issue":"8","key":"2421_CR47","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.14309\/ajg.0000000000000315","volume":"114","author":"KV Kowdley","year":"2019","unstructured":"Kowdley KV, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019;114(8):1202\u201318.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2421_CR48","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1172\/JCI66969","volume":"123","author":"S Guo","year":"2013","unstructured":"Guo S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest. 2013;123(4):1531\u201341.","journal-title":"J Clin Invest"},{"issue":"7","key":"2421_CR49","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","volume":"121","author":"PJ Schmidt","year":"2013","unstructured":"Schmidt PJ, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-\/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood. 2013;121(7):1200\u20138.","journal-title":"Blood"},{"issue":"17","key":"2421_CR50","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1182\/blood-2010-10-315507","volume":"117","author":"KE Finberg","year":"2011","unstructured":"Finberg KE, Whittlesey RL, Andrews NC. Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood. 2011;117(17):4590\u20139.","journal-title":"Blood"},{"key":"2421_CR51","doi-asserted-by":"crossref","unstructured":"Booten S et al. Target TMPRSS6 for the treatment of hereditary hemochromatosis. In 53rd ASH annual meeting abstracts; 2011. p. 1047.","DOI":"10.1182\/blood.V118.21.1047.1047"},{"issue":"11","key":"2421_CR52","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1182\/blood-2006-09-048868","volume":"109","author":"S Gardenghi","year":"2007","unstructured":"Gardenghi S, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109(11):5027\u201335.","journal-title":"Blood"},{"issue":"13","key":"2421_CR53","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1182\/blood-2012-01-405563","volume":"119","author":"NL Parrow","year":"2012","unstructured":"Parrow NL, et al. Decreased hepcidin expression in murine beta-thalassemia is associated with suppression of Bmp\/Smad signaling. Blood. 2012;119(13):3187\u20139.","journal-title":"Blood"},{"issue":"4","key":"2421_CR54","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3324\/haematol.2014.114827","volume":"100","author":"S Rivella","year":"2015","unstructured":"Rivella S. beta-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica. 2015;100(4):418\u201330.","journal-title":"Haematologica"},{"issue":"1","key":"2421_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1182\/blood-2018-07-815928","volume":"133","author":"S Rivella","year":"2019","unstructured":"Rivella S. Iron metabolism under conditions of ineffective erythropoiesis in \u03b2-thalassemia. Blood. 2019;133(1):51\u20138.","journal-title":"Blood"},{"issue":"2","key":"2421_CR56","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1002\/ajh.26056","volume":"96","author":"KM Musallam","year":"2021","unstructured":"Musallam KM, et al. Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later. Am J Hematol. 2021;96(2):E54\u20136.","journal-title":"Am J Hematol"},{"issue":"17","key":"2421_CR57","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2015-07-658419","volume":"126","author":"L Kautz","year":"2015","unstructured":"Kautz L, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood. 2015;126(17):2031\u20137.","journal-title":"Blood"},{"issue":"22","key":"2421_CR58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood.V128.22.259.259","volume":"128","author":"R Chessa","year":"2016","unstructured":"Chessa R, et al. Administration of minihepcidins to animals affected by \u03b2-thalassemia major reduces anemia and splenomegaly. Blood. 2016;128(22):259\u2013259.","journal-title":"Blood"},{"issue":"2","key":"2421_CR59","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","volume":"128","author":"C Casu","year":"2016","unstructured":"Casu C, et al. Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. Blood. 2016;128(2):265\u201376.","journal-title":"Blood"},{"issue":"1","key":"2421_CR60","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.3324\/haematol.2015.133348","volume":"101","author":"C Casu","year":"2016","unstructured":"Casu C, et al. Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. Haematologica. 2016;101(1):e8\u201311.","journal-title":"Haematologica"},{"issue":"17","key":"2421_CR61","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood.2019004719","volume":"136","author":"C Casu","year":"2020","unstructured":"Casu C, et al. Correcting \u03b2-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity. Blood. 2020;136(17):1968\u201379.","journal-title":"Blood"},{"issue":"12","key":"2421_CR62","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1073\/pnas.71.12.4864","volume":"71","author":"J Hofrichter","year":"1974","unstructured":"Hofrichter J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci USA. 1974;71(12):4864\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2421_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/ajh.2830470203","volume":"47","author":"O Castro","year":"1994","unstructured":"Castro O, et al. Improvement of sickle cell anemia by iron-limited erythropoiesis. Am J Hematol. 1994;47(2):74\u201381.","journal-title":"Am J Hematol"},{"issue":"5","key":"2421_CR64","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/archinte.1983.00350050194038","volume":"143","author":"KR Rao","year":"1983","unstructured":"Rao KR, et al. Iron deficiency and sickle cell anemia. Arch Intern Med. 1983;143(5):1030\u20132.","journal-title":"Arch Intern Med"},{"issue":"5339","key":"2421_CR65","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1126\/science.278.5339.873","volume":"278","author":"TM Ryan","year":"1997","unstructured":"Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sickle cell disease. Science. 1997;278(5339):873\u20136.","journal-title":"Science"},{"issue":"39","key":"2421_CR66","doi-asserted-by":"publisher","first-page":"23523","DOI":"10.1074\/jbc.C115.681643","volume":"290","author":"N Das","year":"2015","unstructured":"Das N, et al. Intestine-specific disruption of hypoxia-inducible factor (HIF)-2alpha improves anemia in sickle cell disease. J Biol Chem. 2015;290(39):23523\u20137.","journal-title":"J Biol Chem"},{"issue":"11","key":"2421_CR67","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood.2020006919","volume":"137","author":"NL Parrow","year":"2021","unstructured":"Parrow NL, et al. Dietary iron restriction improves markers of disease severity in murine sickle cell anemia. Blood. 2021;137(11):1553\u20135.","journal-title":"Blood"},{"issue":"7","key":"2421_CR68","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1182\/blood.2021014716","volume":"140","author":"N Nyffenegger","year":"2022","unstructured":"Nyffenegger N, et al. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease. Blood. 2022;140(7):769\u201381.","journal-title":"Blood"},{"issue":"20","key":"2421_CR69","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"1","key":"2421_CR70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333.","journal-title":"N Engl J Med"},{"issue":"10","key":"2421_CR71","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","volume":"32","author":"YZ Ginzburg","year":"2018","unstructured":"Ginzburg YZ, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105\u201316.","journal-title":"Leukemia"},{"issue":"9","key":"2421_CR72","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.clml.2018.05.020","volume":"18","author":"R Mesa","year":"2018","unstructured":"Mesa R, et al. Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18(9):590\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2421_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","volume":"56","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, et al. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017;56:52\u20139.","journal-title":"Leuk Res"},{"issue":"6","key":"2421_CR74","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","volume":"17","author":"A Mullally","year":"2010","unstructured":"Mullally A, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584\u201396.","journal-title":"Cancer Cell"},{"issue":"12","key":"2421_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251995","volume":"16","author":"C Casu","year":"2021","unstructured":"Casu C, et al. Tmprss6-ASO as a tool for the treatment of polycythemia vera mice. PLoS ONE. 2021;16(12): e0251995.","journal-title":"PLoS ONE"},{"issue":"1","key":"2421_CR76","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1124\/jpet.120.000222","volume":"377","author":"TA Zanardi","year":"2021","unstructured":"Zanardi TA, et al. Safety, pharmacokinetic, and pharmacodynamic evaluation of a 2\u2019-(2-methoxyethyl)-D-ribose antisense oligonucleotide-triantenarry N-acetyl-galactosamine conjugate that targets the human transmembrane protease serine 6. J Pharmacol Exp Ther. 2021;377(1):51\u201363.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02421-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02421-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02421-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:36:21Z","timestamp":1680518181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02421-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02421-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"5 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}